11/17/2023

Methyldopa Tablets

Products Affected - Description

- Methyldopa oral tablet, Accord, 250 mg, bottle, 100 count, NDC 16729-0030-01 - discontinued
- Methyldopa oral tablet, Accord, 250 mg, bottle, 500 count, NDC 16729-0030-16 - discontinued
- Methyldopa oral tablet, Accord, 500 mg, bottle, 100 count, NDC 16729-0031-01 - discontinued
- Methyldopa oral tablet, Accord, 500 mg, bottle, 500 count, NDC 16729-0031-16 - discontinued
- Methyldopa oral tablet, Mylan (Viatris), 250 mg, bottle, 100 count, NDC 00378-0611-01 - discontinued
- Methyldopa oral tablet, Mylan (Viatris), 500 mg, bottle, 100 count, NDC 00378-0421-01 - discontinued

Reason for the Shortage

- Accord discontinued methyldopa tablets.
- Chartwell launched methyldopa tablets in November 2023.
- Mylan discontinued methyldopa in June 2021.

Available Products

- Methyldopa oral tablet, Chartwell, 250 mg, bottle, 90 count, NDC 62135-0321-90
- Methyldopa oral tablet, Chartwell, 250 mg, bottle, 180 count, NDC 62135-0321-18
- Methyldopa oral tablet, Chartwell, 500 mg, bottle, 90 count, NDC 62135-0322-90
- Methyldopa oral tablet, Chartwell, 500 mg, bottle, 180 count, NDC 62135-0322-18

Updated

Updated November 17, 2023 by Leslie Jensen, PharmD, Drug Information Specialist. Created November 10, 2023 by Leslie Jensen, PharmD, Drug Information Specialist. © 2023, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.